Advertisement
Mayo Clinic Proceedings Home

Current Issues in the Management of Endometrial Cancer

      Endometrial cancer (EC) remains the most common gynecologic malignancy in the United States. It is expected to become more common as the prevalence of obesity, one of the most common risk factors for EC, increases worldwide. The 2 main histologic subcategories of EC, endometrioid and nonendometrioid EC, show unique molecular aberrations and are responsible for markedly disparate clinical behaviors. The primary treatment of EC is surgery, ie, hysterectomy, removal of the adnexa, and pelvic and para-aortic lymphadenectomy, either via laparotomy or endoscopic techniques. Adjuvant therapy is necessary for patients at high risk of recurrence and consists of vaginal brachytherapy, teletherapy, systemic chemotherapy, or some combination thereof. Multi-institutional trials are in progress in this country and in Europe to better define optimal adjuvant treatment for subsets of patients, as well as the role of surgical staging in reducing both overuse and underuse of radiation therapy. Hormonal therapy is an option for some young women with EC who wish to preserve fertility. This review summarizes the diagnosis and management of EC and discusses current controversies and upcoming investigations pertaining to EC staging and adjuvant treatment.
      BMI (body mass index), CI (confidence interval), EC (endometrial cancer), ERT (estrogen replacement therapy), GOG (Gynecologic Oncology Group), IUD (intrauterine device), LNG (levonorgestrel), MRI (magnetic resonance imaging), MSI (microsatellite instability), NPV (negative predictive value), PMB (postmenopausal bleeding), PORTEC (Postoperative Radiation Therapy in EC), PPV (positive predictive value)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      REFERENCES

        • Parkin DM
        • Bray F
        • Ferlay J
        • Pisani P
        Global cancer statistics, 2002.
        CA Cancer J Clin. 2005; 55: 74-108
        • Amant F
        • Moerman P
        • Neven P
        • Timmerman D
        • Van Limbergen E
        • Vergote I
        Endometrial cancer.
        Lancet. 2005; 366: 491-505
        • Calle EE
        • Kaaks R
        Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.
        Nat Rev Cancer. 2004; 4: 579-591
        • Kaaks R
        • Lukanova A
        • Kurzer MS
        Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review.
        Cancer Epidemiol Biomarkers Prev. 2002; 11: 1531-1543
        • Parslov M
        • Lidegaard O
        • Klintorp S
        • et al.
        Risk factors among young women with endometrial cancer: a Danish case-control study.
        Am J Obstet Gynecol. 2000; 182: 23-29
        • Potischman N
        • Hoover RN
        • Brinton LA
        • et al.
        Case-control study of endogenous steroid hormones and endometrial cancer.
        J Natl Cancer Inst. 1996; 88: 1127-1135
        • Zeleniuch-Jacquotte A
        • Akhmedkhanov A
        • Kato I
        • et al.
        Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study.
        Br J Cancer. 2001; 84: 975-981
        • Calle EE
        • Rodriguez C
        • Walker-Thurmond K
        • Thun MJ
        Overweight, obesity, and mortality from cancer in a prospectively studied cohort of US adults.
        N Engl J Med. 2003; 348: 1625-1638
        • Schouten LJ
        • Goldbohm RA
        • van den Brandt PA
        Anthropometry, physical activity, and endometrial cancer risk: results from The Netherlands Cohort Study.
        J Natl Cancer Inst. 2004; 96: 1635-1638
        • Ayabe T
        • Tsutsumi O
        • Sakai H
        • et al.
        Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer.
        Endocr J. 1997; 44: 419-424
        • Adesanya OO
        • Zhou J
        • Samathanam C
        • Powell-Braxton L
        • Bondy CA
        Insulin-like growth factor 1 is required for G2 progression in the estradiol-induced mitotic cycle.
        Proc Natl Acad Sci U S A. 1999; 96: 3287-3291
        • Gielen SCJP
        • Hanekamp EE
        • Blok LJ
        • Huikeshoven FJ
        • Burger CW
        Steroid-modulated proliferation of human endometrial carcinoma cell lines: any role for insulin-like growth factor signaling?.
        J Soc Gynecol Investig. 2005; 12: 58-64
        • Lacey Jr., JV
        • Potischman N
        • Madigan MP
        • et al.
        Insulin-like growth factors, insulin-like growth factor-binding proteins, and endometrial cancer in postmenopausal women: results from a US case-control study.
        Cancer Epidemiol Biomarkers Prev. 2004; 13: 607-612
        • Suvanto-Luukkonen E
        • Sundstrom H
        • Penttinen J
        • Kauppila A
        • Rutanen EM
        Insulin-like growth factor-binding protein-1: a biochemical marker of endometrial response to progestin during hormone replacement therapy.
        Maturitas. 1995; 22: 255-262
        • Anderson KE
        • Anderson E
        • Mink PJ
        • et al.
        Diabetes and endometrial cancer in the Iowa women's health study.
        Cancer Epidemiol Biomarkers Prev. 2001; 10: 611-616
        • Hardiman P
        • Pillay OC
        • Atiomo W
        Polycystic ovary syndrome and endometrial carcinoma [published correction appears in Lancet. 2003; 362(93890):1082].
        Lancet. 2003; 361: 1810-1812
        • Colbert LH
        • Lacey JV
        • Schairer C
        • Albert P
        • Schatzkin A
        • Albanes D
        Physical activity and risk of endometrial cancer in a prospective cohort study (United States).
        Cancer Causes Control. 2003; 14: 559-567
        • Furberg AS
        • Thune I
        Metabolic abnormalities (hypertension, hyperglycemia and overweight), lifestyle (high energy intake and physical inactivity) and endometrial cancer risk in a Norwegian cohort.
        Int J Cancer. 2003; 104: 669-676
        • McTiernan A
        • Tworoger SS
        • Ulrich CM
        • et al.
        Effect of exercise on serum estrogens in postmenopausal women: a 12-month randomized clinical trial.
        Cancer Res. 2004; 64: 2923-2928
        • Viswanathan AN
        • Feskanich D
        • De Vivo I
        • et al.
        Smoking and the risk of endometrial cancer: results from the Nurses' Health Study.
        Int J Cancer. 2005; 114: 996-1001
        • Lesko SM
        • Rosenberg L
        • Kaufman DW
        • et al.
        Cigarette smoking and the risk of endometrial cancer.
        N Engl J Med. 1985; 313: 593-596
        • Klip H
        • Burger CW
        • Kenemans P
        • Van Leeuwen FE
        Cancer risk associated with subfertility and ovulation induction: a review.
        Cancer Causes Control. 2000; 11: 319-344
        • Hinkula M
        • Pukkala E
        • Kyyronen P
        • Kauppila A
        Grand multiparity and incidence of endometrial cancer: a population-based study in Finland.
        Int J Cancer. 2002; 98: 912-915
        • Chubak J
        • Tworoger SS
        • Yasui Y
        • Ulrich CM
        • Stanczyk FZ
        • McTiernan A
        Associations between reproductive and menstrual factors and postmenopausal sex hormone concentrations.
        Cancer Epidemiol Biomarkers Prev. 2004; 13: 1296-1301
        • Deligeoroglou E
        • Michailidis E
        • Creatsas G
        Oral contraceptives and reproductive system cancer.
        Ann N Y Acad Sci. 2003; : 199-208
        • Anderson GL
        • Judd HL
        • Kaunitz AM
        • Women's Health Initiative Investigators
        • et al.
        Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial.
        JAMA. 2003; 290: 1739-1748
        • Van Gorp T
        • Neven P
        Endometrial safety of hormone replacement therapy: review of literature.
        Maturitas. 2002; 42: 93-104
        • Beral V
        • Bull D
        • Reeves G
        • Million Women Study Collaborators
        Endometrial cancer and hormone-replacement therapy in the Million Women Study.
        Lancet. 2005; 365: 1543-1551
        • Harvey EB
        • Brinton LA
        Second cancer following cancer of the breast in Connecticut, 1935-82.
        Natl Cancer Inst Monogr. 1985; : 99-112
        • Neven P
        • De Muylder X
        • Van Belle Y
        • Van-Hooff I
        • Vanderick G
        Longitudinal hysteroscopic follow-up during tamoxifen treatment [letter].
        Lancet. 1998; 351: 36
        • Baum M
        • Budzar AU
        • Cuzick J
        • ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group
        • et al.
        Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
        Lancet. 2002; 359: 2131-2139
        • Breast International Group (BIG) 1-98 Collaborative Group
        A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
        N Engl J Med. 2005; 353: 2747-2757
        • Bokhman JV
        Two pathogenetic types of endometrial carcinoma.
        Gynecol Oncol. 1983; 15: 10-17
        • Levine RL
        • Cargile CB
        • Blazes MS
        • van Rees B
        • Kurman RJ
        • Ellenson LH
        PTEN mutations and microsatellite instability in complex atypical hyperplasia: a precursor lesion to uterine endometrioid carcinoma.
        Cancer Res. 1998; 58: 3254-3258
        • Emons G
        • Fleckenstein G
        • Hinney B
        • Huschmand A
        • Heyl W
        Hormonal interactions in endometrial cancer.
        Endocr Relat Cancer. 2000; 7: 227-242
        • Clement PB
        • Young RH
        Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects.
        Adv Anat Pathol. 2002; 9: 145-184
        • Ambros RA
        • Sherman ME
        • Zahn CM
        • Bitterman P
        • Kurman RJ
        Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation.
        Hum Pathol. 1995; 26: 1260-1267
        • Zheng W
        • Cao P
        • Zheng M
        • Kramer EE
        • Godwin TA
        p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
        Gynecol Oncol. 1996; 61: 167-174
        • Mutter GL
        • Lin MC
        • Fitzgerald JT
        • et al.
        Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers.
        J Natl Cancer Inst. 2000; 92: 924-930
        • Mutter GL
        • Lin MC
        • Fitzgerald JT
        • Kum JB
        • Eng C
        Changes in endometrial PTEN expression throughout the human menstrual cycle.
        J Clin Endocrinol Metab. 2000; 85: 2334-2338
        • Mutter GL
        • Baak JPA
        • Fitzgerald JT
        • et al.
        Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation.
        Gynecol Oncol. 2001; 83: 177-185
        • Risinger JI
        • Hayes AK
        • Berchuck A
        • Barrett JC
        PTEN/MMAC1 mutations in endometrial cancers.
        Cancer Res. 1997; 57: 4736-4738
        • Lax SF
        • Kendall B
        • Tashiro H
        • Slebos RJ
        • Hedrick L
        The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways.
        Cancer. 2000; 88: 814-824
        • Lagarda H
        • Catasus L
        • Arguelles R
        • Matias-Guiu X
        • Prat J
        K-ras mutations in endometrial carcinomas with microsatellite instability.
        J Pathol. 2001; 193: 193-199
        • Enomoto T
        • Inoue M
        • Perantoni AO
        • et al.
        K-ras activation in premalignant and malignant epithelial lesions of the human uterus.
        Cancer Res. 1991; 51: 5308-5314
        • Scholten AN
        • Creutzberg CL
        • van den Broek LJ
        • Noordijk EM
        • Smit VT
        Nuclear beta-catenin is a molecular feature of type I endometrial carcinoma.
        J Pathol. 2003; 201: 460-465
        • Moreno-Bueno G
        • Hardisson D
        • Sanchez C
        • et al.
        Abnormalities of the APC/beta-catenin pathway in endometrial cancer.
        Oncogene. 2002; 21: 7981-7990
        • Mirabelli-Primdahl L
        • Gryfe R
        • Kim H
        • et al.
        Beta-catenin mutations are specific for colorectal carcinomas with microsatellite instability but occur in endometrial carcinomas irrespective of mutator pathway.
        Cancer Res. 1999; 59: 3346-3351
        • Lax SF
        Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification.
        Virchows Arch. 2004 Mar; 444 (Epub 2004 Jan 28.): 213-223
        • Lax SF
        • Pizer ES
        • Ronnett BM
        • Kurman RJ
        Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression.
        Hum Pathol. 1998; 29: 551-558
        • Duggan BD
        • Felix JC
        • Muderspach Ll
        • Tourgeman D
        • Zheng J
        • Shibata D
        Microsatellite instability in sporadic endometrial carcinoma.
        J Natl Cancer Inst. 1994; 86: 1216-1221
        • Mutter GL
        • Boynton KA
        • Faquin WC
        • Ruiz RE
        • Jovanovic AS
        Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer.
        Cancer Res. 1996; 56: 4483-4486
        • Risinger JI
        • Berchuck A
        • Kohler MF
        • Watson P
        • Lynch HT
        • Boyd J
        Genetic instability of microsatellites in endometrial carcinoma.
        Cancer Res. 1993; 53: 5100-5103
        • Gryfe R
        • Kim H
        • Hsieh ETK
        • et al.
        Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer.
        N Engl J Med. 2000; 342: 69-77
        • Sherman ME
        • Bur ME
        • Kurman RJ
        p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis.
        Hum Pathol. 1995; 26: 1268-1274
        • Peltomaki P
        • Vasen HF
        • International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer
        Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study.
        Gastroenterology. 1997; 113: 1146-1158
        • Miyaki M
        • Konishi M
        • Tanaka K
        • et al.
        Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer [letter].
        Nat Genet. 1997; 17: 271-272
        • Akiyama Y
        • Sato H
        • Yamada T
        • et al.
        Germ-line mutation of the hMSH6/GTPB gene in an atypical hereditary nonpolyposis colorectal cancer kindred.
        Cancer Res. 1997; 57: 3920-3923
        • Kim YB
        • Holschneider CH
        • Ghosh K
        • Nieberg RK
        • Montz FJ
        Progestin alone as primary treatment of endometrial carcinoma in premenopausal women: report of seven cases and review of the literature.
        Cancer. 1997; 79: 320-327
        • Sonoda G
        • du Manoir S
        • Godwin AK
        • et al.
        Detection of DNA gains and losses in primary endometrial carcinomas by comparative genomic hybridization.
        Genes Chromosomes Cancer. 1997; 18: 115-125
        • Niederacher D
        • An HX
        • Cho YJ
        • Hantschmann P
        • Bender HG
        • Beckmann MW
        Mutations and amplification of oncogenes in endometrial cancer.
        Oncology. 1999; 56: 59-65
        • Tashiro H
        • Isacson C
        • Levine R
        • Kurman RJ
        • Cho KR
        • Hedrick L
        p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis.
        Am J Pathol. 1997; 150: 177-185
        • Goodfellow PJ
        • Buttin BM
        • Herzog TJ
        • et al.
        Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers.
        Proc Natl Acad Sci U S A. 2003 May 13; 100 (Epub 2003 May 5.): 5908-5913
        • Tashiro H
        • Lax SF
        • Gaudin PB
        • Isacson C
        • Cho KR
        • Hedrick L
        Microsatellite instability is uncommon in uterine serous carcinoma.
        Am J Pathol. 1997; 150: 75-79
        • Saffari B
        • Jones LA
        • Elnaggar A
        • Felix JC
        • George J
        • Press MF
        Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival.
        Cancer Res. 1995; 55: 5693-5698
        • Halperin R
        • Zehavi S
        • Habler L
        • Hadas E
        • Bukovsky I
        • Schneider D
        Comparative immunohistochemical study of endometrioid and serous papillary carcinoma of endometrium.
        Eur J Gynaecol Oncol. 2001; 22: 122-126
        • Holcomb K
        • Delatorre R
        • Pedemonte B
        • McLeod C
        • Anderson L
        • Chambers J
        E-cadherin expression in endometrioid, papillary serous, and clear cell carcinoma of the endometrium.
        Obstet Gynecol. 2002; 100: 1290-1295
        • Abeler VM
        • Vergote IB
        • Kjorstad KE
        • Trope CG
        Clear cell carcinoma of the endometrium: prognosis and metastatic pattern.
        Cancer. 1996; 78: 1740-1747
        • Wheeler DT
        • Bell KA
        • Kurman RJ
        • Sherman ME
        Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation.
        Am J Surg Pathol. 2000; 24: 797-806
        • Thomas MB
        • Mariani A
        • Cliby WA
        • Keeney GA
        • Podratz KC
        • Dowdy SC
        Role of cytoreduction in stage III and IV uterine papillary serous carcinoma.
        Gynecol Oncol. 2007 Nov; 107 (Epub 2007 Sep 6.): 190-193
        • Pinol V
        • Castells A
        • Andreu M
        • Gastrointestinal Oncology Group of the Spanish Gastroenterological Association
        • et al.
        Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer.
        JAMA. 2005; 293: 1986-1994
        • Karlsson B
        • Granberg S
        • Wikland M
        • et al.
        Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding—a Nordic multicenter study.
        Am J Obstet Gynecol. 1995; 172: 1488-1494
        • DuBeshter B
        • Warshal DP
        • Angel C
        • Dvoretsky PM
        • Lin JY
        • Raubertas RF
        Endometrial carcinoma: the relevance of cervical cytology.
        Obstet Gynecol. 1991; 77: 458-462
        • Gu M
        • Shi W
        • Barakat RR
        • Thaler HT
        • Saigo PE
        Pap smears in women with endometrial carcinoma.
        Acta Cytol. 2001; 45: 555-560
        • Wright Jr, TC
        • Cox JT
        • Massad LS
        • Twiggs LB
        • Wilkinson EJ
        2001 ASCCP-Sponsored Consensus Conference. 2001 consensus guidelines for the management of women with cervical cytological abnormalities.
        JAMA. 2002; 287: 2120-2129
        • Wu HH
        • Schuetz III, MJ
        • Cramer H
        Significance of benign endometrial cells in Pap smears from postmenopausal women.
        J Reprod Med. 2001; 46: 795-798
        • Langer RD
        • Pierce JJ
        • O'Hanlan KA
        • et al.
        Postmenopausal Estrogen/Progestin Interventions Trial. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease.
        N Engl J Med. 1997; 337: 1792-1798
        • Naim NM
        • Mahdy ZA
        • Ahmad S
        • Razi ZRM
        The Vabra aspirator versus the Pipelle device for outpatient endometrial sampling.
        Aust N Z J Obstet Gynaecol. 2007; 47: 132-136
        • Del Priore G
        • Williams R
        • Harbatkin CB
        • Wan LS
        • Mittal K
        • Yang GC
        Endometrial brush biopsy for the diagnosis of endometrial cancer.
        J Reprod Med. 2001; 46: 439-443
        • Dijkhuizen FP
        • Mol BW
        • Brölmann HA
        • Heintz AP
        The accuracy of endometrial sampling in the diagnosis of patients with endometrial carcinoma and hyperplasia: a meta-analysis.
        Cancer. 2000; 89: 1765-1772
        • Epstein E
        • Skoog L
        • Valentin L
        Comparison of Endorette and dilatation and curettage for sampling of the endometrium in women with postmenopausal bleeding.
        Acta Obst Gynecol Scand. 2001; 80: 959-964
        • Dubinsky TJ
        Value of sonography in the diagnosis of abnormal vaginal bleeding.
        J Clin Ultrasound. 2004; 32: 348-353
        • Minagawa Y
        • Sato S
        • Ito M
        • Onohara Y
        • Nakamoto S
        • Kigawa J
        Transvaginal ultrasonography and endometrial cytology as a diagnostic schema for endometrial cancer.
        Gynecol Obstet Invest. 2005; 59 (Epub 2005 Jan 3.): 149-154
        • Van den Bosch T
        • Van Schoubroeck D
        • Ameye L
        • Van Huffel S
        • Timmerman D
        Ultrasound examination of the endometrium before and after Pipelle endometrial sampling.
        Ultrasound Obstet Gynecol. 2005; 26: 283-286
        • Trimble CL
        • Kauderer J
        • Zaino R
        • et al.
        Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study.
        Cancer. 2006; 106: 812-819
        • Bilgin T
        • Ozuysal S
        • Ozan H
        • Atakan T
        Coexisting endometrial cancer in patients with a preoperative diagnosis of atypical endometrial hyperplasia.
        J Obstet Gynaecol Res. 2004; 30: 205-209
        • Merisio C
        • Berretta R
        • De Ioris A
        • et al.
        Endometrial cancer in patients with preoperative diagnosis of atypical endometrial hyperplasia.
        Eur J Obstet Gynecol Reprod Biol. 2005; 122: 107-111
        • de Cecco L
        • Gerbaldo D
        • Fulcheri E
        • et al.
        Endometrial response in sequential cyclic therapy assessed with associated hysteroscopy and histology.
        Maturitas. 1992; 15: 199-208
        • Horn LC
        • Schnurrbusch U
        • Bilek K
        • Hentschel B
        • Einenkel J
        Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment.
        Int J Gynecol Cancer. 2004; 14: 348-353
        • Lai CH
        • Huang HJ
        The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer.
        Curr Opin Obstet Gynecol. 2006; 18: 29-34
        • Stenchever MA
        Droegemueller W Herbst AL Mishel DR Comprehensive Gynecology. 4th ed. Mosby, St Louis, MO2001
        • Randall TC
        • Kurman RJ
        Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40.
        Obstet Gynecol. 1997; 90: 434-440
        • Shamshirsaz AA
        • Withiam-Leitch M
        • Odunsi K
        • Baker T
        • Frederick PJ
        • Lele S
        Young patients with endometrial carcinoma selected for conservative treatment: a need for vigilance for synchronous ovarian carcinomas, case report and literature review.
        Gynecol Oncol. 2007 Mar; 104 (Epub 2007 Jan 9.): 757-760
        • Ramirez PT
        • Frumovitz M
        • Bodurka DC
        • Sun CC
        • Levenback C
        Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review.
        Gynecol Oncol. 2004; 95: 133-138
        • Kurman RJ
        • Kaminski PF
        • Norris HJ
        The behavior of endometrial hyperplasia: a long-term study of “untreated” hyperplasia in 170 patients.
        Cancer. 1985; 56: 403-412
        • Gallup DG
        • Stock RJ
        Adenocarcinoma of the endometrium in women 40 years of age or younger.
        Obstet Gynecol. 1984; 64: 417-420
        • Wildemeersch D
        • Dhont M
        Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system.
        Am J Obst Gynecol. 2003; 188: 1297-1298
        • Montz FJ
        • Bristow RE
        • Bovicelli A
        • Tomacruz R
        • Kurman RJ
        Intrauterine progesterone treatment of early endometrial cancer.
        Am J Obstet Gynecol. 2002; 186: 651-657
        • Dhar KK
        • NeedhiRajan T
        • Koslowski M
        • Woolas RP
        Is levonorgestrel intrauterine system effective for treatment of early endometrial cancer? report of four cases and review of the literature.
        Gynecol Oncol. 2005; 97: 924-927
        • Giannopoulos T
        • Butler-Manuel S
        • Tailor A
        Levonorgestrel-releasing intrauterine system (LNG-IUS) as a therapy for endometrial carcinoma.
        Gynecol Oncol. 2004; 95: 762-764
        • Lethaby AE
        • Cooke I
        • Rees M
        Progesterone or progestogen-releasing intrauterine systems for heavy menstrual bleeding.
        Cochrane Database Syst Rev. 2005 Oct; 19 (CD002126.)
        • Ronnerdag M
        • Odlind V
        Health effects of long-term use of the intrauterine levonorgestrel-releasing system: a follow-up study over 12 years of continuous use.
        Acta Obstet Gynecol Scand. 1999; 78: 716-721
        • Jones K
        • Georgiou M
        • Hyatt D
        • Spencer T
        • Thomas H
        Endometrial adenocarcinoma following the insertion of a Mirena IUCD.
        Gynecol Oncol. 2002; 87: 216-218
        • Abu J
        • Brown L
        • Ireland D
        Endometrial adenocarcinoma following insertion of the levonorgestrel-releasing intrauterine system (mirena) in a 36-year-old woman.
        Int J Gynecol Cancer. 2006; 16: 1445-1447
        • American College of Obstetricians and Gynecologists Committee on Gynecologic Practice
        ACOG committee opinion. No. 337: noncontraceptive uses of the levonorgestrel intrauterine system.
        Obstet Gynecol. 2006; 107: 1479-1482
        • Morrow CP
        • Bundy BN
        • Kurman RJ
        • et al.
        Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.
        Gynecol Oncol. 1991; 40: 55-65
        • Rotman M
        • Azziz H
        • Halpern J
        • Schwartz D
        • Sohn C
        • Choi K
        Endometrial carcinoma: influence of prognostic factors on radiation management.
        Cancer. 1993; 71: 1471-1479
        • Thigpen JT
        • Blessing JA
        • DiSaia PJ
        • Yordan E
        • Carson LF
        • Evers C
        A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study.
        J Clin Oncol. 1994; 12: 1408-1414
        • Aapro MS
        • van Wijk FH
        • Bolis G
        • European Organisation for Research and Treatment of Cancer (EORTC) Gynecological Cancer Group
        • et al.
        Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomized study (55872) by the EORTC Gynaecological Cancer Group.
        Ann Oncol. 2003; 14: 441-448
        • Fleming GF
        • Brunetto VL
        • Cella D
        • et al.
        Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        J Clin Oncol. 2004; 22: 2159-2166
        • Thigpen JT
        • Brady MF
        • Homesley HD
        • et al.
        Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        J Clin Oncol. 2004; 22: 3902-3908
        • Randall ME
        • Filiaci VL
        • Muss H
        • et al.
        Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study.
        J Clin Oncol. 2006 Jan 1; 24 (Epub 2005 Dec 5.): 36-44
        • Chao CK
        • Grigsby PW
        • Perez CA
        • Mutch DG
        • Herzog T
        • Camel HM
        Medically inoperable stage I endometrial carcinoma: a few dilemmas in radiotherapeutic management.
        Int J Radiat Oncol Biol Phys. 1996; 34: 27-31
        • Nguyen TV
        • Petereit DG
        High-dose-rate brachytherapy for medically inoperable stage I endometrial cancer.
        Gynecol Oncol. 1998; 71: 196-203
        • Connor JP
        • Andrews JI
        • Anderson B
        • Buller RE
        Computed tomography in endometrial carcinoma.
        Obstet Gynecol. 2000; 95: 692-696
        • Kinkel K
        • Kaji Y
        • Yu KK
        • et al.
        Radiologic staging in patients with endometrial cancer: a meta-analysis.
        Radiology. 1999; 212: 711-718
        • Cragun JM
        • Havrilesky LJ
        • Calingaert B
        • et al.
        Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer.
        J Clin Oncol. 2005 Jun 1; 23 (Epub 2005 Feb 28.): 3668-3675
        • Kilgore LC
        • Partridge EE
        • Alvarez RD
        • et al.
        Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling.
        Gynecol Oncol. 1995; 56: 29-33
        • Mariani A
        • Webb MJ
        • Galli L
        • Podratz KC
        Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer.
        Gynecol Oncol. 2000; 76: 348-356
        • Podratz KC
        • Mariani A
        • Webb MJ
        Staging and therapeutic value of lymphadenectomy in endometrial cancer [editorial].
        Gynecol Oncol. 1998; 70: 163-164
        • Solhjem MC
        • Petersen IA
        • Haddock MG
        Vaginal brachytherapy alone is sufficient adjuvant treatment of surgical stage I endometrial cancer.
        Int J Radiat Oncol Biol Phys. 2005; 62: 1379-1384
        • American College of Obstetricians and Gynecologists
        Clinical management of endometrial cancer.
        Obstet Gynecol. 2005; 106: 413-425
        • Creutzberg CL
        GOG-99: ending the controversy regarding pelvic radiotherapy for endometrial carcinoma [editorial]?.
        Gynecol Oncol. 2004; 92: 740-743
        • Creutzberg CL
        • van Putten WL
        • Koper PC
        • PORTEC Study Group
        • et al.
        Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial.
        Lancet. 2000; 355: 1404-1411
        • Keys HM
        • Roberts JA
        • Brunetto VL
        • et al.
        A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study.
        Gynecol Oncol. 2004; 92: 744-751
        • Berman ML
        Adjuvant radiotherapy following properly staged endometrial cancer: what role [editorial]?.
        Gynecol Oncol. 2004; 92: 737-739
        • Alektiar KM
        • Venkatraman E
        • Chi DS
        • Barakat RR
        Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.
        Int J Radiat Oncol Biol Phys. 2005; 62: 111-117
        • Anderson JM
        • Stea B
        • Hallum AV
        • Rogoff E
        • Childers J
        High-dose-rate postoperative vaginal cuff irradiation alone for stage IB and IC endometrial cancer.
        Int J Radiat Oncol Biol Phys. 2000; 46: 417-425
        • Fanning J
        Long-term survival of intermediate risk endometrial cancer (stage IG3, IC, II) treated with full lymphadenectomy and brachytherapy without teletherapy.
        Gynecol Oncol. 2001; 82: 371-374
        • Horowitz NS
        • Peters III, WA
        • Smith MR
        • Drescher CW
        • Atwood M
        • Mate TP
        Adjuvant high dose rate vaginal brachytherapy as treatment of stage I and II endometrial carcinoma.
        Obstet Gynecol. 2002; 99: 235-240
        • Larson DM
        • Broste SK
        • Krawisz BR
        Surgery without radiotherapy for primary treatment of endometrial cancer.
        Obstet Gynecol. 1998; 91: 355-359
        • Mohan DS
        • Samuels MA
        • Selim MA
        • et al.
        Long-term outcomes of therapeutic pelvic lymphadenectomy for stage I endometrial adenocarcinoma.
        Gynecol Oncol. 1998; 70: 165-171
        • Ng TY
        • Perrin LC
        • Nicklin JL
        • Cheuk R
        • Crandon AJ
        Local recurrence in high-risk node-negative stage I endometrial carcinoma treated with postoperative vaginal vault brachytherapy.
        Gynecol Oncol. 2000; 79: 490-494
        • Orr Jr, JW
        • Holimon JL
        • Orr PF
        Stage I corpus cancer: is teletherapy necessary?.
        Am J Obstet Gynecol. 1997; 176: 777-788
        • Straughn Jr, JM
        • Huh WK
        • Kelly FJ
        • et al.
        Conservative management of stage I endometrial carcinoma after surgical staging.
        Gynecol Oncol. 2002; 84: 194-200
        • Trimble EL
        • Kosary C
        • Park RC
        Lymph node sampling and survival in endometrial cancer.
        Gynecol Oncol. 1998; 71: 340-343
        • Occelli B
        • Narducci F
        • Lanvin D
        • et al.
        De novo adhesions with extraperitoneal endosurgical para-aortic lymphadenectomy versus transperitoneal laparoscopic para-aortic lymphadenectomy: a randomized experimental study.
        Am J Obstet Gynecol. 2000; 183: 529-533
        • Elliott P
        • Green D
        • Coates A
        The efficacy of postoperative vaginal irradiation in preventing vaginal recurrence in endometrial cancer.
        Int J Gynecol Cancer. 1994; 4: 84-93
        • Kadar N
        • Malfetano JH
        • Homesley HD
        Determinants of survival of surgically staged patients with endometrial carcinoma histologically confined to the uterus: implications for therapy.
        Obstet Gynecol. 1992; 80: 655-659
        • Creasman WT
        • Morrow CP
        • Bundy BN
        • Homesley HD
        • Graham JE
        • Heller PB
        Surgical pathologic spread patterns of endometrial cancer: a Gynecologic Oncology Group study.
        Cancer. 1987; 60: 2035-2041
        • Fielding LP
        • Fenoglio-Preiser CM
        • Freedman LS
        The future of prognostic factors in outcome prediction for patients with cancer.
        Cancer. 1992; 70: 2367-2377
        • Inoue Y
        • Obata K
        • Abe K
        • et al.
        The prognostic significance of vascular invasion by endometrial carcinoma.
        Cancer. 1996; 78: 1447-1451
        • Mariani A
        • Webb MJ
        • Keeney GL
        • Haddock MG
        • Calori G
        • Podratz KC
        Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?.
        Am J Obstet Gynecol. 2000; 182: 1506-1519
        • Schink JC
        • Rademaker AW
        • Miller DS
        • Lurain JR
        Tumor size in endometrial cancer.
        Cancer. 1991; 67: 2791-2794
        • Wilson TO
        • Podratz KC
        • Gaffey TA
        • Malkasian Jr, GD
        • O'Brien PC
        • Naessens JM
        Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma.
        Am J Obstet Gynecol. 1990; 162: 418-423
        • Aalders J
        • Abeler V
        • Kolstad P
        • Onsrud M
        Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients.
        Obstet Gynecol. 1980; 56: 419-427
        • Carey MS
        • O'Connell GJ
        • Johanson CR
        • et al.
        Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium.
        Gynecol Oncol. 1995; 57: 138-144
        • Mariani A
        • Dowdy SC
        • Keeney GL
        • Long HJ
        • Lesnick TG
        • Podratz KC
        High-risk endometrial cancer subgroups: candidates for target-based adjuvant therapy.
        Gynecol Oncol. 2004; 95: 120-126
        • Mariani A
        • Keeney GL
        • Aletti G
        • Webb MJ
        • Haddock MG
        • Podratz KC
        Endometrial carcinoma: paraaortic dissemination.
        Gynecol Oncol. 2004; 92: 833-838
        • Mariani A
        • Webb MJ
        • Keeney GL
        • Podratz KC
        Routes of lymphatic spread: a study of 112 consecutive patients with endometrial cancer.
        Gynecol Oncol. 2001; 81: 100-104
        • McMeekin DS
        • Lashbrook D
        • Gold M
        • Johnson G
        • Walker JL
        • Mannel R
        Analysis of FIGO Stage IIIc endometrial cancer patients.
        Gynecol Oncol. 2001; 81: 273-278
        • Mariani A
        • Dowdy SC
        • Keeney GL
        • Haddock MG
        • Lesnick TG
        • Podratz KC
        Predictors of vaginal relapse in stage I endometrial cancer.
        Gynecol Oncol. 2005; 97: 820-827
        • Hogberg T
        • Rosenberg P
        • Kristensen G
        • et al.
        A randomized phase-III study on adjuvant treatment with radiation (RT) ± chemotherapy (CT) in early-stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991) [abstract 5503].
        J Clin Oncol. 2007; 25
        • Maggino T
        • Romagnolo C
        • Landoni F
        • Sartori E
        • Zola P
        • Gadducci A
        An analysis of approaches to the management of endometrial cancer in North America: a CTF study.
        Gynecol Oncol. 1998; 68: 274-279
        • Podczaski E
        • Kaminski P
        • Gurski K
        Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery.
        Gynecol Oncol. 1992; 47: 323-327
        • Mariani A
        • Webb MJ
        • Keeney GL
        • Calori G
        • Podratz KC
        Hematogenous dissemination in corpus cancer.
        Gynecol Oncol. 2001; 80: 233-238
        • Mariani A
        • Webb MJ
        • Keeney GL
        • Haddock MG
        • Aletti G
        • Podratz KC
        Stage IIIC endometrioid corpus cancer includes distinct subgroups.
        Gynecol Oncol. 2002; 87: 112-117
        • Mariani A
        • Webb MJ
        • Keeney GL
        • Aletti G
        • Podratz KC
        Predictors of lymphatic failure in endometrial cancer.
        Gynecol Oncol. 2002; 84: 437-442
        • Mariani A
        • Webb MJ
        • Kenney GL
        • Aletti G
        • Podratz KC
        Endometrial cancer: predictors of peritoneal failure.
        Gynecol Oncol. 2003; 89: 236-242
        • Lehoczky O
        • Bosze P
        • Ungar L
        • Tottossy B
        Stage I endometrial carcinoma: treatment of nonoperable patients with intracavitary radiation therapy alone.
        Gynecol Oncol. 1991; 43: 211-216
        • Varia M
        • Rosenman J
        • Halle J
        • Walton L
        • Currie J
        • Fowler W
        Primary radiation therapy for medically inoperable patients with endometrial carcinoma—stages I-II.
        Int J Radiat Oncol Biol Phys. 1987; 13: 11-15
        • Walsh C
        • Holschneider C
        • Hoang Y
        • Tieu K
        • Karlan B
        • Cass I
        Coexisting ovarian malignancy in young women with endometrial cancer.
        Obstet Gynecol. 2005; 106: 693-699
        • Lee TS
        • Jung JY
        • Kim JW
        • et al.
        Feasibility of ovarian preservation in patients with early stage endometrial carcinoma.
        Gynecol Oncol. 2007 Jan; 104 (Epub 2006 Aug 2.): 52-57
        • Morice P
        • Fourchotte V
        • Sideris L
        • Gariel C
        • Duvillard P
        • Castaigne D
        A need for laparoscopic evaluation of patients with endometrial carcinoma selected for conservative treatment.
        Gynecol Oncol. 2005; 96: 245-248
        • Creasman WT
        • Henderson D
        • Hinshaw W
        • Clarke-Pearson DL
        Estrogen replacement therapy in the patient treated for endometrial cancer.
        Obstet Gynecol. 1986; 67: 326-330
        • Suriano KA
        • McHale M
        • McLaren CE
        • Li KT
        • Re A
        • DiSaia PJ
        Estrogen replacement therapy in endometrial cancer patients: a matched control study.
        Obstet Gynecol. 2001; 97: 555-560
        • Barakat RR
        • Bundy BN
        • Spirtos NM
        • Bell J
        • Mannel RS
        Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group study.
        J Clin Oncol. 2006; 24: 587-592
        • American College of Obstetricians and Gynecologists
        ACOG committee opinion: hormone replacement therapy in women treated for endometrial cancer.
        Int J Gynecol Obstet. 2001; 73: 283-284
        • Ota T
        • Yoshida M
        • Kimura M
        • Kinoshita K
        Clinicopathologic study of uterine endometrial carcinoma in young women aged 40 years and younger.
        Int J Gynecol Cancer. 2005; 15: 657-662
        • Ben-Shachar I
        • Vitellas KM
        • Cohn DE
        The role of MRI in the conservative management of endometrial cancer.
        Gynecol Oncol. 2004; 93: 233-237
        • Minderhoud-Bassie W
        • Treurniet FE
        • Koops W
        • Chadha-Ajwani S
        • Hage JC
        • Huikeshoven FJ
        Magnetic resonance imaging (MRI) in endometrial carcinoma: preoperative estimation of depth of myometrial invasion.
        Acta Obstet Gynecol Scand. 1995; 74: 827-831
        • Nakao Y
        • Yokoyama M
        • Hara K
        • et al.
        MR imaging in endometrial carcinoma as a diagnostic tool for the absence of myometrial invasion.
        Gynecol Oncol. 2006 Aug; 102 (Epub 2006 Feb 15.): 343-347
        • Huang SY
        • Jung SM
        • Ng KK
        • Chang YC
        • Lai CH
        Ovarian metastasis in a nulliparous woman with endometrial adenocarcinoma failing conservative hormonal treatment.
        Gynecol Oncol. 2005; 97: 652-655
        • Kaku T
        • Yoshikawa H
        • Tsuda H
        • et al.
        Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
        Cancer Lett. 2001; 167: 39-48
        • Ollikainen M
        • Abdel-Rahman WM
        • Moisio AL
        • et al.
        Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome?.
        J Clin Oncol. 2005 Jul 20; 23 (Epub 2005 Apr 18.): 4609-4616
        • Parc YR
        • Halling KC
        • Burgart LJ
        • et al.
        Microsatellite instability and hMLH1/hMSH2 expression in young endometrial carcinoma patients: associations with family history and histopathology.
        Int J Cancer. 2000; 86: 60-66
        • Dunlop MG
        • Farrington SM
        • Carothers AD
        • et al.
        Cancer risk associated with germline DNA mismatch repair gene mutations.
        Hum Mol Genet. 1997; 6: 105-110
        • Kunkel TA
        • Erie DA
        DNA mismatch repair.
        Ann Rev Biochem. 2005; 74: 681-710
        • Marti TM
        • Kunz C
        • Fleck O
        DNA mismatch repair and mutation avoidance pathways.
        J Cell Physiol. 2002; 191: 28-41
        • Boltenberg A
        • Furgyik S
        • Kullander S
        Familial cancer aggregation in cases of adenocarcinoma corporis uteri.
        Acta Obstet Gynecol Scand. 1990; 69: 249-258
        • Vasen HF
        • Watson P
        • Mecklin JP
        • Lynch HT
        New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC.
        Gastroenterology. 1999; 116: 1453-1456
        • Hendriks YM
        • Jagmohan-Changur S
        • van der Klift HM
        • et al.
        Heterozygous mutations in PMS2 cause hereditary nonpolyposis colorectal carcinoma (Lynch syndrome).
        Gastroenterology. 2006; 130: 312-322
        • Umar A
        • Boland CR
        • Terdiman JP
        • et al.
        Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability.
        J Natl Cancer Inst. 2004; 96: 261-268
        • Lynch HT
        • Lynch JF
        The Lynch syndrome: melding natural history and molecular genetics to genetic counseling and cancer control.
        Cancer Control. 1996; 3: 13-19
        • Renkonen-Sinisalo L
        • Bützow R
        • Leminen A
        • Mecklin J
        • Järvinen HJ
        Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome.
        Int J Cancer. 2007; 120: 821-824
        • Schmeler KM
        • Lynch HT
        • Chen LM
        • et al.
        Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome.
        N Engl J Med. 2006; 354: 261-269
        • Aarnio M
        • Sankila R
        • Pukkala E
        • et al.
        Cancer risk in mutation carriers of DNA-mismatch-repair genes.
        Int J Cancer. 1999; 81: 214-218
        • Renkonen-Sinisalo L
        • Bützow R
        • Leminen A
        • Lehtovirta P
        • Mecklin JP
        • Järvinen HJ
        Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome.
        Int J Cancer. 2007; 120: 821-824
        • Lindor NM
        • Petersen GM
        • Hadley DW
        • et al.
        Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review.
        JAMA. 2006; 296: 1507-1517
        • Vasen HF
        • Möslein G
        • Alonso A
        • et al.
        Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer).
        J Med Genet. 2007 Jun; 44 (Epub 2007 Feb 27.): 353-362
        • Bertagnolli MM
        Surgical prevention of cancer.
        J Clin Oncol. 2005; 23: 324-332
        • Lynch HT
        • Watson P
        • Shaw TG
        • et al.
        Clinical impact of molecular genetic diagnosis, genetic counseling, and management of hereditary cancer: part II: hereditary nonpolyposis colorectal carcinoma as a model.
        Cancer. 1999; 86: 2457-2463
        • Lynch HT
        • Krush AJ
        • Larsen AL
        • Magnuson CW
        Endometrial carcinoma: multiple primary malignancies, constitutional factors, and heredity.
        Am J Med Sci. 1966; 252: 381-390
        • Sandles LG
        • Shulman LP
        • Elias S
        • et al.
        Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancer.
        Gynecol Oncol. 1992; 47: 167-171
        • Gruber SB
        • Thompson WD
        • Cancer and Steroid Hormone Study Group
        A population-based study of endometrial cancer and familial risk in younger women.
        Cancer Epidemiol Biomarkers Prev. 1996; 5: 411-417
        • Grady D
        • Gebretsadik T
        • Kerlikowske K
        • Ernster V
        • Petitti D
        Hormone replacement therapy and endometrial cancer risk: a meta-analysis.
        Obstet Gynecol. 1995; 85: 304-313
        • Sasco AJ
        Epidemiology of breast cancer: an environmental disease?.
        APMIS. 2001; 109: 321-332
        • MacMahon B
        • Cole P
        • Lin TM
        • et al.
        Age at first birth and breast cancer risk.
        Bull World Health Organ. 1970; 43: 209-221
        • MacMahon B
        Risk factors for endometrial cancer.
        Gynecol Oncol. 1974; 2: 122-129
        • Brinton LA
        • Berman ML
        • Mortel R
        • et al.
        Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study.
        Am J Obstet Gynecol. 1992; 167: 1317-1325
        • Henderson BE
        • Casagrande JT
        • Pike MC
        • Mack T
        • Rosario I
        • Duke A
        The epidemiology of endometrial cancer in young women.
        Br J Cancer. 1983; 47: 749-756
        • Kazerouni N
        • Schairer C
        • Friedman HB
        • Lacey Jr, JV
        • Greene MH
        Family history of breast cancer as a determinant of the risk of developing endometrial cancer: a nationwide cohort study [letter].
        J Med Genet. 2002; 39: 826-832
        • Kelsey JL
        • LiVolsi VA
        • Holford TR
        • et al.
        A case-control study of cancer of the endometrium.
        Am J Epidemiol. 1982; 116: 333-342
        • Anderson DE
        • Badzioch MD
        Familial breast cancer risks: effects of prostate and other cancers.
        Cancer. 1993; 72: 114-119
        • Parazzini F
        • La Vecchia C
        • Negri E
        • Franceschi S
        • Tozzi L
        Family history of breast, ovarian and endometrial cancer and risk of breast cancer.
        Int J Epidemiol. 1993; 22: 614-618
        • Lynch HT
        • Krush AJ
        • Lemon HM
        • Kaplan AR
        • Condit PT
        • Bottomley RH
        Tumor variation in families with breast cancer.
        JAMA. 1972; 222: 1631-1635
        • Beiner ME
        • Finch A
        • Rosen B
        • et al.
        The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations: a prospective study.
        Gynecol Oncol. 2007 Jan; 104 (Epub 2006 Sep 8.): 7-10